• Explore /
  • Poster
  • / Neoadjuvant low-dose radiotherapy, tislelizumab, combined with albumin-bound paclitaxel and cisplatin in resectable locally advanced head and neck squamous cell carcinoma (NeoRTPC02): The first-stage result from an open label, single-arm, two stage, phase II clinical trial.

Neoadjuvant low-dose radiotherapy, tislelizumab, combined with albumin-bound paclitaxel and cisplatin in resectable locally advanced head and neck squamous cell carcinoma (NeoRTPC02): The first-stage result from an open label, single-arm, two stage, phase II clinical trial.

Abstract Poster

Authors

null

Zhigang Liu

The Cancer Center of Affiliated Dongguan Hospital of Southern Medical University, Dongguan, Guangdong, China

Zhigang Liu , Yingpeng Peng , Xiaotao Huang , Lizhong Liang , Guihua Zhong , Ye Liu , Haiyu Hong , Qiaodan Liu , Zhijie Liu , Dong Wang , Wen Jiang

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Head and Neck Cancer

Track

Head and Neck Cancer

Sub Track

Local-Regional Disease

Clinical Trial Registration Number

NCT05343325

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr 6078)

DOI

10.1200/JCO.2023.41.16_suppl.6078

Abstract #

6078

Poster Bd #

70

Abstract Disclosures

Similar Posters

Poster

2024 ASCO Genitourinary Cancers Symposium

Preliminary efficacy and safety results from ReBirth: A phase II study of risk-based bladder-sparing therapy for MIBC.

Preliminary efficacy and safety results from ReBirth: A phase II study of risk-based bladder-sparing therapy for MIBC.

First Author: Yijun Shen

First Author: Xiaomin Ou

First Author: Thomas Powles

First Author: Jingpei Li